+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Diagnostics Market by Cancer Type, Technology, Specimen Type, Age Group, Application, End User - Global Forecast 2026-2032- Product Image
Cancer Diagnostics Market by Cancer Type, Technology, Specimen Type, Age Group, Application, End User - Global Forecast 2026-2032- Product Image
Sale

Cancer Diagnostics Market by Cancer Type, Technology, Specimen Type, Age Group, Application, End User - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011653
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Diagnostics Market is projected to reach USD 56.19 Billion in 2026. It is expected to continue growing at a CAGR of 12.26%, reaching USD 112.67 Billion by 2032.

Cancer diagnostics is moving from episodic, symptom-led testing toward earlier, molecularly informed detection across screening, diagnosis, treatment selection, and recurrence monitoring. The clinical need is substantial: the World Health Organization's IARC GLOBOCAN 2022 estimates about 20 million new cancer cases and 9.7 million cancer deaths worldwide, with the burden expected to rise sharply as populations age and exposure to preventable risk factors persists.

Demand is being shaped by high-volume pathology, imaging, companion diagnostics, next-generation sequencing, liquid biopsy, immunohistochemistry, cytology, HPV testing, and point-of-care testing. Health systems are prioritizing diagnostics that shorten time to diagnosis, improve tumor characterization, support precision oncology, and expand access to guideline-recommended screening for breast, cervical, colorectal, lung, and prostate cancers.

Transformative Shifts in the Cancer Diagnostics Landscape

The cancer diagnostics landscape is being transformed by the convergence of molecular testing, digital pathology, advanced imaging, and decentralized sample collection. Tumor profiling is increasingly embedded in routine oncology workflows because targeted therapies and immunotherapies often require validated biomarkers such as EGFR, ALK, HER2, BRCA, MSI, PD-L1, and NTRK.

At the same time, laboratories face pressure to improve turnaround time, reimbursement evidence, sample traceability, and interoperability with electronic health records. The shift from single-gene assays to multi-gene panels and comprehensive genomic profiling is raising expectations for analytical validity, clinical utility, external quality assessment, and standardized reporting across hospital laboratories, reference laboratories, and oncology networks.

Cumulative Impact of Artificial Intelligence on Cancer Diagnostics

Artificial intelligence is having a cumulative impact across radiology, pathology, genomics, and workflow orchestration. In imaging, AI supports lesion detection, triage, segmentation, and longitudinal comparison, while in pathology it helps quantify biomarkers, prioritize suspicious slides, and improve consistency in high-volume review.

Regulators are increasingly evaluating AI-enabled medical devices, and the U.S. FDA has listed hundreds of authorized AI and machine-learning-enabled devices, with radiology representing the largest category. For cancer diagnostics, the practical value of AI depends on prospective validation, bias monitoring, cybersecurity, explainability, human oversight, and integration into clinician-supervised decision pathways rather than standalone automation.

Key Regional Insights Across Cancer Diagnostics

Asia-Pacific is becoming a major opportunity base as China, India, Japan, South Korea, and Australia invest in oncology infrastructure, molecular laboratories, digital health, and population screening. North America remains a leading region for cancer diagnostics due to high oncology spending, established screening programs, broad adoption of companion diagnostics, and mature regulatory pathways for in vitro diagnostics and laboratory-developed tests.

Latin America is improving access through public-private diagnostic networks, with Brazil and Mexico acting as important demand centers for pathology, imaging, HPV testing, and molecular oncology. Europe is shaped by national cancer plans, organized screening, IVDR implementation, and cross-border research networks, while the European Health Data Space is designed to strengthen data-driven oncology innovation. The Middle East is expanding precision medicine through tertiary cancer centers, digital health programs, and national genomics initiatives, while Africa's priority is scalable access to pathology, HPV testing, imaging, and basic oncology diagnostics in line with WHO cancer control goals.

Key Group Insights for Global Cancer Diagnostics Adoption

ASEAN is focused on affordable cancer screening, laboratory capacity, pathology workforce development, and regional referral networks to improve access across diverse health systems. The GCC is investing heavily in precision oncology, digital health, centralized specialty care, and national genomics initiatives, strengthening demand for advanced molecular diagnostics and AI-enabled imaging workflows.

The European Union is pivotal because IVDR, cancer screening recommendations, and Europe's Beating Cancer Plan influence diagnostic quality, evidence generation, and market access. BRICS countries represent large-volume growth driven by cancer burden, expanding middle-class access, public oncology investment, and domestic diagnostic manufacturing. The G7 anchors high-value adoption through advanced oncology reimbursement, clinical trial density, biomarker-driven therapy use, and regulatory science, while NATO countries overlap significantly with major diagnostic innovation hubs in North America and Europe, supporting resilient supply chains for reagents, imaging equipment, semiconductors, cloud infrastructure, and cybersecurity-enabled health data systems.

Key Country Insights Shaping Cancer Diagnostics Demand

The United States leads in companion diagnostics, oncology genomics, liquid biopsy innovation, and AI-enabled imaging, supported by large cancer centers and payer scrutiny around clinical utility. Canada emphasizes equitable screening and provincial laboratory networks, while Mexico and Brazil are expanding access to pathology, immunohistochemistry, HPV testing, imaging, and molecular oncology within mixed public-private systems.

The United Kingdom, Germany, France, Italy, and Spain are advancing national cancer strategies, genomics programs, organized screening, and digital pathology adoption, while Russia maintains demand for imaging and pathology modernization. China is scaling domestic IVD innovation and oncology testing capacity; India is prioritizing affordable diagnostics, HPV testing, and tertiary cancer care expansion; Japan and South Korea remain leaders in precision oncology, companion diagnostics, and high-quality imaging; and Australia combines strong screening participation, research infrastructure, and digital health adoption.

Actionable Recommendations for Cancer Diagnostics Leaders

Industry leaders should prioritize clinically validated diagnostics that demonstrate measurable improvements in detection, staging, therapy selection, recurrence monitoring, or care pathway efficiency. Evidence packages should include analytical performance, real-world clinical utility, health-economic impact, and workflow fit for oncologists, pathologists, radiologists, laboratory directors, and public screening programs.

Organizations should also invest in interoperable platforms, AI governance, decentralized sample logistics, cybersecurity, and regulatory-ready quality systems. Strategic partnerships with cancer centers, payers, biobanks, public health agencies, and screening programs can accelerate adoption, while tiered pricing, local training, and regional manufacturing can improve access in emerging markets.

Research Methodology for Cancer Diagnostics Intelligence

This executive summary is based on secondary research from authoritative public sources, including WHO, IARC GLOBOCAN, national cancer institutes, regulatory agencies, peer-reviewed oncology literature, clinical guideline bodies, and public health program documentation. Market interpretation considers epidemiology, diagnostic guidelines, technology adoption, reimbursement structures, regulatory requirements, and regional healthcare capacity.

The analysis triangulates data across disease burden, screening participation, installed diagnostic infrastructure, regulatory developments, precision medicine adoption, and evidence standards for oncology testing. Insights are validated through consistency checks across clinical evidence, policy direction, and technology deployment patterns to support decision-making for manufacturers, laboratories, investors, and healthcare providers.

Conclusion: Cancer Diagnostics as a Precision Oncology Engine

Cancer diagnostics is becoming a central pillar of precision oncology, public health screening, and value-based cancer care. Momentum is being driven by rising cancer incidence, biomarker-linked therapies, AI-enabled interpretation, and expanding access to molecular, pathology, cytology, and imaging-based diagnostics.

The most competitive organizations will combine scientific validity, operational scalability, regulatory discipline, data security, and equitable access strategies. As health systems seek earlier detection and more personalized treatment, cancer diagnostics will remain one of the most strategically important segments of global healthcare.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cancer Diagnostics Market, by Cancer Type
7.1. Hematological Cancers
7.1.1. Leukemia
7.1.2. Lymphoma
7.1.3. Multiple Myeloma
7.2. Solid Tumors
7.2.1. Breast Cancer
7.2.2. Colorectal Cancer
7.2.3. Lung Cancer
7.2.4. Prostate Cancer
8. Cancer Diagnostics Market, by Technology
8.1. Flow Cytometry
8.1.1. Cell Sorting
8.1.2. Multiparameter Flow Cytometry
8.2. Imaging
8.2.1. Computed Tomography
8.2.2. Magnetic Resonance Imaging
8.2.3. Positron Emission Tomography
8.2.4. Ultrasound
8.3. Immunohistochemistry
8.3.1. Chromogenic
8.3.2. Fluorescent
8.4. In Situ Hybridization
8.5. Molecular Diagnostics
8.5.1. Microarray
8.5.2. PCR
8.5.3. Sequencing
9. Cancer Diagnostics Market, by Specimen Type
9.1. Tissue
9.2. Blood
9.3. Bone Marrow
9.4. Urine
9.5. Saliva
10. Cancer Diagnostics Market, by Age Group
10.1. Pediatric
10.2. Adult
10.3. Geriatric
11. Cancer Diagnostics Market, by Application
11.1. Screening & Early Detection
11.2. Initial Diagnosis
11.3. Prognosis & Risk Stratification
11.4. Therapy Selection
11.5. Treatment Monitoring
11.6. Recurrence Monitoring
12. Cancer Diagnostics Market, by End User
12.1. Ambulatory Care
12.2. Diagnostic Laboratories
12.3. Hospitals
12.4. Research Institutes
13. Asia-Pacific Cancer Diagnostics Market
14. Europe Cancer Diagnostics Market
15. North America Cancer Diagnostics Market
16. Latin America Cancer Diagnostics Market
17. Africa Cancer Diagnostics Market
18. Middle East Cancer Diagnostics Market
19. NATO Cancer Diagnostics Market
20. G7 Cancer Diagnostics Market
21. BRICS Cancer Diagnostics Market
22. European Union Cancer Diagnostics Market
23. ASEAN Cancer Diagnostics Market
24. GCC Cancer Diagnostics Market
25. China Cancer Diagnostics Market
26. United States Cancer Diagnostics Market
27. Japan Cancer Diagnostics Market
28. India Cancer Diagnostics Market
29. Germany Cancer Diagnostics Market
30. United Kingdom Cancer Diagnostics Market
31. Australia Cancer Diagnostics Market
32. France Cancer Diagnostics Market
33. South Korea Cancer Diagnostics Market
34. Italy Cancer Diagnostics Market
35. Canada Cancer Diagnostics Market
36. Russia Cancer Diagnostics Market
37. Brazil Cancer Diagnostics Market
38. Mexico Cancer Diagnostics Market
39. Spain Cancer Diagnostics Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Abbott Laboratories
41.2. Agilent Technologies, Inc.
41.3. Becton, Dickinson and Company
41.4. Bio-Rad Laboratories, Inc.
41.5. bioMérieux SA
41.6. Canon Medical Systems Corporation
41.7. Danaher Corporation
41.8. DiaSorin S.p.A.
41.9. F. Hoffmann-La Roche Ltd
41.10. Fujifilm Corporation
41.11. GE HealthCare Technologies Inc.
41.12. Hologic, Inc.
41.13. Illumina, Inc.
41.14. Myriad Genetics, Inc.
41.15. NeoGenomics Laboratories, Inc.
41.16. PerkinElmer, Inc.
41.17. QIAGEN N.V.
41.18. Quest Diagnostics Incorporated
41.19. Siemens Healthineers AG
41.20. Sysmex Corporation
41.21. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL CANCER DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CANCER DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CANCER DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CANCER DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. NATO CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. NATO CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. G7 CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. G7 CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. GCC CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. GCC CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. CHINA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. JAPAN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. INDIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. GERMANY CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. FRANCE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. ITALY CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. CANADA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. MEXICO CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SPAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL HEMATOLOGICAL CANCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL HEMATOLOGICAL CANCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL HEMATOLOGICAL CANCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CELL SORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CELL SORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CELL SORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MULTIPARAMETER FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MULTIPARAMETER FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MULTIPARAMETER FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CHROMOGENIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CHROMOGENIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CHROMOGENIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL FLUORESCENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL FLUORESCENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL FLUORESCENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL MICROARRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL MICROARRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL MICROARRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL BONE MARROW MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL BONE MARROW MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL BONE MARROW MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL SCREENING & EARLY DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL SCREENING & EARLY DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL SCREENING & EARLY DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL PROGNOSIS & RISK STRATIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL PROGNOSIS & RISK STRATIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL PROGNOSIS & RISK STRATIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL THERAPY SELECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL THERAPY SELECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL THERAPY SELECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL TREATMENT MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL TREATMENT MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL TREATMENT MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL AMBULATORY CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL AMBULATORY CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL AMBULATORY CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 157. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 158. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 159. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 160. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 161. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 162. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 163. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 164. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 165. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 166. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 167. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 168. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 170. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 171. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 172. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 173. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 174. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 175. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 176. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 177. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 178. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 179. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 180. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 181. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 183. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 184. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 185. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 186. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 187. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 188. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 189. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 190. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 191. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 192. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 193. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 194. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 196. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 197. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 198. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 199. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 200. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 201. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 202. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 203. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 204. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 205. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 206. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 207. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 208. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 209. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 210. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 211. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 212. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 213. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 214. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 215. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 216. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 217. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 218. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 219. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 220. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. NATO CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 222. NATO CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 223. NATO CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 224. NATO CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 225. NATO CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 226. NATO CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 227. NATO CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 228. NATO CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 229. NATO CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 230. NATO CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 231. NATO CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 232. NATO CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 233. NATO CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 234. G7 CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 235. G7 CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 236. G7 CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 237. G7 CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 238. G7 CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 239. G7 CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 240. G7 CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 241. G7 CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 242. G7 CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 243. G7 CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 244. G7 CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 245. G7 CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 246. G7 CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 247. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 248. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 249. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 250. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 251. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 252. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 253. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 254. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 255. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 256. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 257. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 258. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 259. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 273. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 274. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 275. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 276. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 277. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 278. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 279. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 280. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 281. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 282. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 283. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 284. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 285. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 286. GCC CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 287. GCC CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 288. GCC CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 289. GCC CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 290. GCC CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 291. GCC CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 292. GCC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 293. GCC CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 294. GCC CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 295. GCC CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 296. GCC CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 297. GCC CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 298. GCC CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 299. CHINA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 300. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 301. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 302. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 303. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 304. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 305. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 306. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 307. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 308. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 309. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 310. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 311. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 312. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 313. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 314. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 315. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 316. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 317. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 318. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 319. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 320. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 321. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 322. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 323. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 324. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 325. JAPAN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 326. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 327. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 328. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 329. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 330. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 331. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 332. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 333. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 334. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 335. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 336. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 337. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 338. INDIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 339. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 340. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 341. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 342. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 343. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 344. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 345. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 346. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 347. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 348. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 349. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 350. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 351. GERMANY CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 352. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 353. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 354. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 355. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 356. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 357. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 358. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
TABLE 359. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 360. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 361. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 362. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 363. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 364. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 365. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 366. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 367. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 368. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 369. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 370. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
TABLE 371. UNITED KINGDOM CANCER DIAGNOSTICS MARKET S

Companies Mentioned

The companies featured in this Cancer Diagnostics market report include:
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Canon Medical Systems Corporation
  • Danaher Corporation
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Corporation
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 56.19 Billion
Forecasted Market Value ( USD ) by 2032 $ 112.67 Billion
Compound Annual Growth Rate12.2%
Regions CoveredGlobal
No. of Companies Mentioned22

Related Topics

Related Reports

Canine Cancer Screening Market - Global Forecast 2026-2032 - Product Image

Canine Cancer Screening Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Head & Neck Cancer Diagnostics Market by Product Type, Technology, Cancer Type, Application, End User - Global Forecast 2026-2032 - Product Image

Head & Neck Cancer Diagnostics Market by Product Type, Technology, Cancer Type, Application, End User - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Blood Cancer Diagnostics - Global Strategic Business Report - Product Image

Blood Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 372 Pages
  • Global
From
Liver Cancer Diagnostics - Global Strategic Business Report - Product Image

Liver Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 275 Pages
  • Global
From
Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities - Product Image

Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities

  • Report
  • 278 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.